Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 2/20 | 0.52 |
| ▸ | GABRD | O14764 | 2/20 | 0.52 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.52 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.52 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.52 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.52 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.52 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.52 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.52 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.52 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.52 |
| ▸ | GABRE | P78334 | 2/20 | 0.52 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.52 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.52 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.52 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | GRM8 | O00222 | 1/20 | 0.52 |
| ▸ | GRM6 | O15303 | 1/20 | 0.52 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25128372 | 1.00 | GABRP (0.52) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL677269 | 0.85 | TSHR (0.38) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL21663697 | 0.85 | ALOX15 (0.50) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL677268 | 0.85 | TSHR (0.38) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL25128645 | 0.84 | GABRP (0.47) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Hydrochloric Acid SCHEMBL27645430 | 0.83 | ALOX15 (0.48) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL17659956 | 0.83 | TSHR (0.37) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1672087 | 0.82 | GRM8 (0.65) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL25128863 | 0.81 | CYP1A2 (0.48) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL19248428 | 0.80 | TSHR (0.41) | GRIK1SLC1A3SLC1A2SLC1A1GRIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220135639-A1 | PROCESS FOR PREPARING A GIP/GLP1 DUAL AGONIST | ELI LILLY AND COMPANY | 2022-05-05 | — | — | US | disclosed |
| WO-2018037119-A1 | PRODRUGS ACTIVATED BY REACTIVE OXYGEN SPECIES FOR USE IN THE TREATMENT OF INFLAMMATORY DISEASES AND CANCER | DANMARKS TEKNISKE UNIVERSITET (DK) | 2018-03-01 | — | — | WO | disclosed |
| EP-3122743-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | Azevan Pharmaceuticals, Inc. (US) | 2017-02-01 | — | — | EP | disclosed |
| WO-2015148962-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | AZEVAN PHARMACEUTICALS, INC. (US) | 2015-10-01 | — | — | WO | disclosed |
| EP-2587919-A1 | METHODS FOR TREATING POST TRAUMATIC STRESS DISORDER | Azevan Pharmaceuticals, Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| WO-2012003436-A1 | METHODS FOR TREATING POST TRAUMATIC STRESS DISORDER | AZEVAN PHARMACEUTICALS, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135639-A1 | PROCESS FOR PREPARING A GIP/GLP1 DUAL AGONIST | GLP1R, GIPR, GPR119 | GABRP 825/4885GABRD 397/4885GABRA1 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.